<DOC>
	<DOCNO>NCT00001003</DOCNO>
	<brief_summary>To evaluate compare 3 anti-pneumocystis regimen plus zidovudine ( AZT ) person advance HIV disease T4 cell count &lt; 200 cells/mm3 . To establish range pentamidine ( PEN ) deposition AIDS patient participate ACTG 021 ACTG 081 . To identify factor ( breathe pattern , pulmonary function ) may important affect actual dose deliver give patient . The specific system use deliver PEN lung may determine whether therapeutically effective dose attain lung . Therefore , study establish amount PEN deposit lung patient enrol protocol ACTG 021 ACTG 081 , treat PEN administer Marquest Respirgard II nebulizer .</brief_summary>
	<brief_title>A Study Pentamidine Prevention Pneumocystis Carinii Pneumonia</brief_title>
	<detailed_description>The specific system use deliver PEN lung may determine whether therapeutically effective dose attain lung . Therefore , study establish amount PEN deposit lung patient enrol protocol ACTG 021 ACTG 081 , treat PEN administer Marquest Respirgard II nebulizer . Approximately 4 week patient ACTG 021 ACTG 081 begin PEN aerosol therapy prevention PCP , patient undergo first radioactive aerosol study . The patient inhales mist sit his/her back gamma camera . The resulting picture outline lung . This mist contain single dose PEN mix small amount radioactivity ( 99m-technetium ertechnetate ) . The gamma camera determine particle deposit lung . The radioactivity exposure equivalent typical xray rib . This procedure take 45 minute ; 6 hour later another 30-minute gamma camera image obtain . Blood withdrawn measure blood level PEN do ACTG 021 ACTG 081 . The entire procedure repeat near end prophylactic schedule ( 10-12 month start aerosol PEN treatment ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed : Local radiation Kaposi 's sarcoma . Patients successfully complete course study therapy acute Pneumocystis carinii pneumonia ( PCP ) meet inclusion criterion Protocol ACTG 021 ACTG 081 randomize aerosolize pentamidine arm . Patients currently receive aerosolize pentamidine prophylactic therapy PCP . Exclusion Criteria The following patient exclude : Those enrol ACTG 021 randomize oral prophylaxis arm . Those enrolled ACTG 081 randomize trimethoprim / sulfamethoxazole dapsone arm . Prior Treatment : Excluded within 2 week study entry : Transfusions blood red blood cell . CoExisting Condition : Significant adverse effect . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Nebulizers Vaporizers</keyword>
	<keyword>Lung</keyword>
	<keyword>Administration , Inhalation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>